Conversa Health offers an innovative, automated virtual healthcare chatbot that provides an automated conversation to help people monitor their health.
Conversa recently raised $12 million in Series B funding; the round was co-led by Builders Venture Capital and Northwell Ventures. Other investors included UH Ventures, P5 Health Ventures, and Nassau Street Ventures. All totaled, Conversa has raised more than $26 million in funding.
The company plans to use the funding to scale up its virtual healthcare communication platform. Conversa plans to continue helping healthcare providers and pharmacists save both time and money while tracking patients’ progress and needs.
Conversa partners with healthcare systems to virtually converse with patients to manage and monitor their healthcare needs. The platform creates a profile for each patient based on their medical records, symptoms, and insurance claims. With machine learning, the platform can set the level of contact and personalise messages based on the patient’s profile.
Healthcare providers can use the Conversa platform to create automated healthcare conversations via chatbot. The simulated conversations center around chronic-condition management, pre- and post-surgery, post-hospital discharge, and adherence to medication. Likewise, pharmacies can use the platform to educate people about their medications as well as sending reminders to take their medications.
The platform also assists patients monitor and track the progress of their conditions. For example, a person can record their blood pressure using the app, and if necessary, the Conversa platform can prompt the person to contact their healthcare provider.
Moreover, Conversa has launched an ensemble of COVID-19 programs for organisations and businesses to ensure their employees are healthy before they return to work. Using the platform’s automated messaging, workers can get screened before work, track their symptoms, and receive lab results.
Source: Healthcare Weekly